메뉴 건너뛰기




Volumn 4, Issue 2, 2013, Pages 167-173

Insulin degludec: A significant advancement in ultralong-acting basal insulin

Author keywords

Basal insulin; Diabetes; Insulin; Insulin analogs; Insulin degludec

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN DEGLUDEC; INSULIN RECEPTOR; LONG ACTING INSULIN; SOMATOMEDIN C;

EID: 84899840963     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-013-0047-6     Document Type: Editorial
Times cited : (15)

References (22)
  • 1
    • 84864285795 scopus 로고    scopus 로고
    • Position statement of the American diabetes association (ADA) and the European Association for the study of diabetes (EASD)
    • Management of hyperglycaemia in type 2 diabetes: A patientcentered approach
    • Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patientcentered approach. Position statement of the American diabetes association (ADA) and the European Association for the study of diabetes (EASD). Diabetologia. 2012;55:1577-96.
    • (2012) Diabetologia , vol.55 , pp. 1577-1596
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3    Diamant, M.4    Ferrannini, E.5    Nauck, M.6
  • 2
    • 2542576404 scopus 로고    scopus 로고
    • Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes
    • Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614-20.
    • (2004) Diabetes , vol.53 , pp. 1614-1620
    • Heise, T.1    Nosek, L.2    Ronn, B.B.3    Endahl, L.4    Heinemann, L.5    Kapitza, C.6
  • 3
    • 33746538357 scopus 로고    scopus 로고
    • Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart
    • Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med. 2006;23(8):879-86.
    • (2006) Diabet Med , vol.23 , Issue.8 , pp. 879-886
    • Ashwell, S.G.1    Gebbie, J.2    Home, P.D.3
  • 4
    • 25844511202 scopus 로고    scopus 로고
    • Early hypoglycaemia after accidental intramuscular injection of insulin glargine
    • Karges B, Boehm BO, Karges W. Early hypoglycaemia after accidental intramuscular injection of insulin glargine. Diabet Med. 2005;22(10):1444-5.
    • (2005) Diabet Med , vol.22 , Issue.10 , pp. 1444-1445
    • Karges, B.1    Boehm, B.O.2    Karges, W.3
  • 6
    • 84879558241 scopus 로고    scopus 로고
    • Diabetes Attitudes, Wishes and Needs second study (DAWN2™): Cross-national benchmarking of diabetes-related psychosocial outcomes for people with diabetes
    • Nicolucci A, Kovacs Burns K, Holt RIG, Comaschi M, Hermanns N, Ishii H, et al. Diabetes Attitudes, Wishes and Needs second study (DAWN2™): Cross-national benchmarking of diabetes-related psychosocial outcomes for people with diabetes. Diabet Med. 2013;30(7):767-77.
    • (2013) Diabet Med , vol.30 , Issue.7 , pp. 767-777
    • Nicolucci, A.1    Kovacs, B.K.2    Holt, R.I.G.3    Comaschi, M.4    Hermanns, N.5    Ishii, H.6
  • 7
    • 84879589380 scopus 로고    scopus 로고
    • Diabetes Attitudes, Wishes and Needs second study (DAWN2™): Crossnational benchmarking indicators for family members living with people with diabetes
    • Kovacs Burns K, Nicolucci A, Holt RIG, Willaing I, Hermanns N, Kalra S, et al. Diabetes Attitudes, Wishes and Needs second study (DAWN2™): crossnational benchmarking indicators for family members living with people with diabetes. Diabet Med. 2013;30(7):778-88.
    • (2013) Diabet Med , vol.30 , Issue.7 , pp. 778-788
    • Kovacs, B.K.1    Nicolucci, A.2    Holt, R.I.G.3    Willaing, I.4    Hermanns, N.5    Kalra, S.6
  • 8
    • 84859746575 scopus 로고    scopus 로고
    • Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec
    • Kurzhals P, Heise T, Strauss HM, Bøttcher SG, Granhall C, Haahr H, Jonassen I. Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec. Diabetes. 2011;60(Suppl 1):LB12.
    • (2011) Diabetes , vol.60 , Issue.SUPPL. 1
    • Kurzhals, P.1    Heise, T.2    Strauss, H.M.3    Bøttcher, S.G.4    Granhall, C.5    Haahr, H.6    Jonassen, I.7
  • 10
    • 84859883969 scopus 로고    scopus 로고
    • Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine
    • Heise T, Hövelmann U, Nosek L, Bøttcher SG, Granhall C, Haahr H. Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Diabetes. 2011;60(Suppl 1):LB11.
    • (2011) Diabetes , vol.60 , Issue.SUPPL. 1
    • Heise, T.1    Hövelmann, U.2    Nosek, L.3    Bøttcher, S.G.4    Granhall, C.5    Haahr, H.6
  • 11
    • 84864375931 scopus 로고    scopus 로고
    • Insulin degludec: Four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes
    • Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14: 859-64.
    • (2012) Diabetes Obes Metab , vol.14 , pp. 859-864
    • Heise, T.1    Hermanski, L.2    Nosek, L.3    Feldman, A.4    Rasmussen, S.5    Haahr, H.6
  • 12
    • 79956110739 scopus 로고    scopus 로고
    • Insulin degludec in type 1 diabetes: Randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine
    • Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, et al. Insulin degludec in type 1 diabetes: randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care. 2011;34: 661-5.
    • (2011) Diabetes Care , vol.34 , pp. 661-665
    • Birkeland, K.I.1    Home, P.D.2    Wendisch, U.3    Ratner, R.E.4    Johansen, T.5    Endahl, L.A.6
  • 13
    • 79956136690 scopus 로고    scopus 로고
    • A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naïve people with type 2 diabetes: A randomized, controlled trial
    • Heise T, Tack CJ, Cuddihy R, Davidson J, Gouet D, Liebl A, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naïve people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. 2011;34:669-74.
    • (2011) Diabetes Care , vol.34 , pp. 669-674
    • Heise, T.1    Tack, C.J.2    Cuddihy, R.3    Davidson, J.4    Gouet, D.5    Liebl, A.6
  • 14
    • 84869842163 scopus 로고    scopus 로고
    • Insulin degludec versus glargine in insulin naive patients with type 2 diabetes: A randomized treat to target trial (BEGIN Once Long)
    • Zinman B, Prillis-Tsimikar A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, et al. Insulin degludec versus glargine in insulin naive patients with type 2 diabetes: a randomized treat to target trial (BEGIN Once Long). Diabetes Care. 2012;35:2464-71.
    • (2012) Diabetes Care , vol.35 , pp. 2464-2471
    • Zinman, B.1    Prillis-Tsimikar, A.2    Cariou, B.3    Handelsman, Y.4    Rodbard, H.W.5    Johansen, T.6
  • 15
    • 84871937855 scopus 로고    scopus 로고
    • Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: A pre-planned meta-analysis of phase 3 trials
    • Ratner RE, Gough SCL, Mathieu C, Del Prato S, Bode B, Mersebach H, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15:175-84.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 175-184
    • Ratner, R.E.1    Gough, S.C.L.2    Mathieu, C.3    Del Prato, S.4    Bode, B.5    Mersebach, H.6
  • 16
    • 84874858316 scopus 로고    scopus 로고
    • Efficacy and safety of insulin degludec in a flexible dosing regimen vs. insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): A 26-week randomized, treat-totarget trial with a 26-week extension
    • Mathieu C, Hollander P, Miranda-Palma B, Cooper J, Franek E, Russell-Jones D, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs. insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-totarget trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98(3):1154-62.
    • (2013) J Clin Endocrinol Metab , vol.98 , Issue.3 , pp. 1154-1162
    • Mathieu, C.1    Hollander, P.2    Miranda-Palma, B.3    Cooper, J.4    Franek, E.5    Russell-Jones, D.6
  • 17
    • 84899847563 scopus 로고    scopus 로고
    • Insulin degludec given in a flexible once-daily dosing regimen does not compromise efficacy or safety in type 2 diabetes
    • Rana A, Meneghini L, Atkin S, Bain SC, Gough S, Raz I, et al. Insulin degludec given in a flexible once-daily dosing regimen does not compromise efficacy or safety in type 2 diabetes. Prim Care Diabetes 2013;7(1):85-85.
    • (2013) Prim Care Diabetes , vol.7 , Issue.1 , pp. 85
    • Rana, A.1    Meneghini, L.2    Atkin, S.3    Bain, S.C.4    Gough, S.5    Raz, I.6
  • 18
    • 49149121730 scopus 로고    scopus 로고
    • Management of hypothyroidism in adults
    • Vaidya B, Pearce SHS. Management of hypothyroidism in adults. BMJ 2008;337.
    • (2008) BMJ , pp. 337
    • Vaidya, B.1    Pearce, S.H.S.2
  • 19
    • 0026721384 scopus 로고
    • Effect of "missed" pills on oral contraceptive effectiveness
    • Letterie GS, Chow GE. Effect of "missed" pills on oral contraceptive effectiveness. Obstet Gynecol. 1992;79:979-82.
    • (1992) Obstet Gynecol , vol.79 , pp. 979-982
    • Letterie, G.S.1    Chow, G.E.2
  • 20
    • 77952641591 scopus 로고    scopus 로고
    • What is the optimal therapy for young males with hypogonadotropic hypogonadism?
    • Han TS, Bouloux PM. What is the optimal therapy for young males with hypogonadotropic hypogonadism? Clin Endocrinol. 2010;72:731-7.
    • (2010) Clin Endocrinol , vol.72 , pp. 731-737
    • Han, T.S.1    Bouloux, P.M.2
  • 21
    • 84899855629 scopus 로고    scopus 로고
    • Available at, Accessed 27 Oct
    • FDA withholds insulin degludec approval; wants safety data. Available at: http://www.familypracticenews.com/news/diabetes-endocrinology-metabolism/single-article/fda-withholds-insulin-degludec-approval-wants-safety-data/db819817d382fd2744a59c04cad79c62.html. Accessed 27 Oct 2013.
    • (2013) FDA Withholds Insulin Degludec Approval; Wants Safety Data
  • 22
    • 84886397925 scopus 로고    scopus 로고
    • Newer basal insulin analogues: Degludec, detemir, glargine
    • Kalra S. Newer basal insulin analogues: degludec, detemir, glargine. J Pak Med Ass. 2013;63(11): 1442-4.
    • (2013) J Pak Med Ass , vol.63 , Issue.11 , pp. 1442-1444
    • Kalra, S.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.